Pure Global
NCT06345612

Impact of Eccentric Training in Hypoxia With Creatine on Metabolic Control and VO2max in Patients With Type 1 Diabetes

Impact of Eccentric Training Conducted in the Conditions of Normobaric Hypoxia, Normoxia and Creatine Supplementation on Metabolic Control, Muscle Strength Level, Maximum Oxygen Consumption (VO2max) in Patients With Type 1diabetes Mellitus
Silesian Centre for Heart Diseases·ClinicalTrials.gov·behavioralRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes
Drug/Device/Intervention
hypoxia
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Silesian Centre for Heart Diseases
Location
Zabrze, Poland
Timeline & enrollment
Phase
N/A
Start date
Nov 15, 2023
End date
Jul 01, 2025
Enrollment
28 participants
Primary outcome

Metabolic control of diabetes,Time in range,Time below range,Maximum oxygen consumption (VO2max)

Summary

Exercise plays an important role in treatment of diabetes. In recent years exercise training
 in normobaric hypoxia is used in training programs for athletes and in rehabilitation and
 also commercially. The aim of the study is to assess the impact of eccentric training
 conducted in conditions of normobaric hypoxia or normoxia and creatine supplementation on
 metabolic control: profile and stability of glucose concentration, HbA1c value, hypoglycemia
 and insulin demand, as well as the level of muscle strength, VO2max and anthropometric
 parameters

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06345612
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06345612 through Pure Global AI's free database. This phase not specified trial is sponsored by Silesian Centre for Heart Diseases and is currently Recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.